1. Eris acquires 51% stake in Swiss Parenterals for INR 637.5 Crore (US$79.7 Million).
2. Sun Pharma to acquire 16.33% stake in Surgimatix for US$3.05 Million.
3. Cipla partners with CSIR-CDRI on ophthalmic antifungal treatment.
4. Glenmark partners with Pfizer to launch Abrocitinib in India.
5. US fund Platinum in talks to buy Inventia Health.
6. Cipla eyes acquisitions, inorganic partnerships in US market.
7. Thyrocare Technologies to acquire Think Health Diagnostics.
8. Biocon Biologics inks pact with Sandoz for sale of 2 biosimilar products Trastuzumab and Bevacizumab in Australia.
9. Viatris and Idorsia announce collaboration for the global development and commercialization of Selatogrel and Cenerimod for an upfront of US$350 Million plus milestone and royalty payments.
10. Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for US$253 Million.
11. Eli Lilly partner BioAge raises US$170 Million for obesity treatment.
12. Latigo Biotherapeutics raises US$135 Million for non-opioid painkillers.
13. TILT Biotherapeutics awarded US$2 Million grant from U.S. Department of Defense (DOD) for a three-year project on treatment for ovarian cancer using the company’s TILT-123 asset.
14. RaySearch have announces the acquisition of DrugLog from Pharmacolog for the purchase price of SEK 7 Million(US$ 0.67 Million).

1. Aagami CEO Dinesh Jain to attend DCAT week 2024 in New York City (March 18-21). Meeting calendar almost full. Contact us very soon, please. 
2. Awarded contract extensions from 2 clients.
3. Aagami to attend BIO International Convention 2024 in San Diego. Partnering system expected to open shortly.
4. Aagami is celebrating its 21^st Anniversary and are offering special pricing for new assignments until March 31^st, 2024.

For Partnering/Licensing/ Co-development:

1. Licensing available for Japan: Market ready Denosumab biosimilar to PROLIA^® & XGEVA^®. Other high potential Biosimilars are also available for multiple regions.
2. Partnering/Licensing: IP for a small molecule NSAID combination for Migraine and other indications using 505(b)(2).
3. Seeking Acquisition /JV – Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).
4. Seeking Licensing/Co-development:  A phase 2 (USA) stage Tizanidine patch using proprietary ILTS technology for management of spasticity from Japanese client.

For Acquisition:

1. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.
2. IP/Asset sale: A small molecule NSAID combination for Migraine and other indications using 505(b)(2).
3. Asset sale –US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

Seeking Investment:

1. Seeking US$15 Million: Nose to brain technology development company targeting orphan diseases such as FrontoTemporal Dementia (FTD), Alzheimer’s disease, Dementia with Lewy Bodies and Parkinson's disease.
2. Seeking US$5 Million: Integrated Autoimmune company leading the Next Healthcare Revolution by Uncovering the drivers of autoimmune diseases to advance therapeutic assets.
3. Seeking US$5 Million: A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. Fulfills an unmet need for treating Bacterial Dysentery.
4. Seeking US$5 Million: Midwest US based Pharma with Phase 2 stage First-in-Class Non-Opioid Analgesic NCE for Pain Relief.

Hope you found the content useful. We welcome your feedback and queries.